John Libbey Eurotext

Hématologie

MENU

Sickle cell disease and risk of haematological malignancies Volume 27, issue 4, Juillet-Août 2021

Authors
1 Association Drepagreffe
2 Centre de référence de la drépanocytose
3 IMRB-Inserm U955, Bât. UITC-EFS, Créteil, France
* Tirés à part

The occurrence of haematological malignancies years after allograft rejection or gene therapy for sickle cell disease requires reflection on the potential role of the disease and its treatments.